Kura Oncology与Kyowa Kirin宣布Ziftomenib治疗一线急性髓系白血病关键性3期Komet-017试验首位患者完成给药

美股速递
Sep 30

Kura Oncology与Kyowa Kirin宣布,针对一线急性髓系白血病(AML)的Ziftomenib关键性3期Komet-017试验已完成首位患者给药。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10